Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity

Chien-Chang Shen1,*
Hong-Jen Liang2,*
Chia-Chi Wang3
Mei-Hsiu Liao4
Tong-Rong Jan1

1Department and Graduate Institute of Veterinary Medicine, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan; 2Innovation and Incubation Center, Yuanpei University, Hsinchu, Taiwan; 3School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan; 4Division of Isotope Application, Institute of Energy Research, Taoyuan, Taiwan

*These authors contributed equally to this work

Background: It was recently reported that iron oxide nanoparticles attenuated antigen-specific humoral responses and T cell cytokine expression in ovalbumin-sensitized mice. It is presently unclear whether iron oxide nanoparticles influence T helper 1 cell-mediated immunity. The present study aimed to investigate the effect of iron oxide nanoparticles on delayed-type hypersensitivity (DTH), whose pathophysiology requires the participation of T helper 1 cells and macrophages.

Methods: DTH was elicited by a subcutaneous challenge with ovalbumin to the footpads of mice sensitized with ovalbumin. Iron oxide nanoparticles (0.2–10 mg iron/kg) were administered intravenously 1 hour prior to ovalbumin sensitization. Local inflammatory responses were examined by footpad swelling and histological analysis. The expression of cytokines by splenocytes was measured by enzyme-linked immunosorbent assay.

Results: Administration of iron oxide nanoparticles, in a dose-dependent fashion, significantly attenuated inflammatory reactions associated with DTH, including the footpad swelling, the infiltration of T cells and macrophages, and the expression of interferon-γ, interleukin-6, and tumor necrosis factor-α in the inflammatory site. Iron oxide nanoparticles also demonstrated a suppressive effect on ovalbumin-stimulated production of interferon-γ by splenocytes and the phagocytic activity of splenic CD11b+ cells.

Conclusion: These results demonstrated that a single dose of iron oxide nanoparticles attenuated DTH reactions by suppressing the infiltration and functional activity of T helper 1 cells and macrophages in response to antigen stimulation.

Keywords: iron oxide nanoparticle, T cell, macrophage, delayed-type hypersensitivity

Introduction

Engineered nanoparticles have been increasingly applied in many fields, including photonics, catalysis, magnetics, and biomedical applications. Among various nanomaterials, iron oxide nanoparticles possess a unique property of superparamagnetism that confers advantages for biomedical applications, including the generation of heat in alternating magnetic fields, and an ability to guide specific targeting by an external magnetic field. This property plays a central role in the development of iron oxide nanoparticles for contrast enhancement, targeted delivery of drugs or genes, tissue engineering, cancer thermal therapy, magnetic transfection, chelation therapy, and tissue engineering.1–7 Given the widespread potential applications of iron oxide nanoparticles and their impending commercialization, exposure of humans and animals to iron oxide nanoparticles is likely to increase significantly in the near future. Therefore, evaluation of the health impact of iron oxide nanoparticles is important.
Medicinal preparations of superparamagnetic iron oxide nanoparticles have been used as diagnostic contrasting agents for magnetic resonance imaging of focal liver lesions. It has been well documented that systemically administered iron oxide nanoparticles are rapidly engulfed by the reticuloendothelial system, with the spleen being one of the major organs for particle distribution. Accordingly, the impact of iron oxide nanoparticles on the functionality of immune cells has become a focus of research. Exposure of primary macrophages to iron oxide nanoparticles results in a marked induction of oxidative stress and apoptosis. In addition, iron oxide nanoparticles suppress the phagocytic activity of RAW 264.7 cells—a murine macrophage line—and increase the production of tumor necrosis factor-α (TNF-α) and nitric oxide. Murine studies have also demonstrated that intratracheal instillation of iron oxide nanoparticles elicits proinflammatory and prooxidative effects, as evidenced by a marked infiltration of inflammatory cells in lung tissues and a diminished level of intracellular glutathione in bronchoalveolar lavage cells. In addition to macrophages, T cells are also a sensitive target in the immune system to iron oxide nanoparticles. Oral and intravenous administrations of iron oxide nanoparticles alter T cell cellularity in normal nonsensitized mice. It has been reported that serum levels of interleukin-2 (IL-2), IL-10, and interferon-γ (IFN-γ) are elevated in mice intravenously administered with iron oxide nanoparticles. Moreover, it was recently reported that exposure to iron oxide nanoparticles suppresses humoral immunity and influences antigen-specific T cell reactivity. Collectively, these results clearly demonstrate that the functionality of macrophages and T cells is modulated by iron oxide nanoparticles upon in vitro and in vivo exposure.

A previous study showed that both T helper 1 (Th1)- and Th2-type immune responses are suppressed by iron oxide nanoparticle administration, in which Th2 cells appear less sensitive. Moreover, direct exposure of ovalbumin-primed splenocytes to iron oxide nanoparticles primarily inhibits antigen-specific Th1 cytokine expression. On the basis of these results, it was hypothesized that iron oxide nanoparticles may modulate Th1 cell-mediated immune responses. A murine model of delayed-type hypersensitivity (DTH), whose pathophysiology requires the functions of antigen-activated Th1 cells and macrophages, was employed to investigate the effect of iron oxide nanoparticles on Th1 cell-mediated immunity.

Materials and methods

Reagents and chemicals

All reagents were purchased from Sigma-Aldrich Corporation (St Louis, MO) unless otherwise stated. Enzyme-linked immunosorbent assay sets for cytokine measurement were purchased from BD Biosciences (San Jose, CA). Cell culture supplies were obtained from Thermo Scientific HyClone (Logan, UT). Resovist® (Bayer Schering Pharma AG, Berlin, Germany)—a commercial preparation of carboxydextran-coated iron oxide nanoparticles containing 28 mg iron/mL—was used in the present study. The iron oxide nanoparticles of Resovist exhibited a monodisperse population of particles with an average diameter of 58.7 nm, as measured using a particle size analyzer (Zetasizer Nano-S, Malvern Instruments Ltd, Malvern, Worcestershire, UK). The crystalline core of ferucarbotran (Resovist) is composed of magnetite (Fe₃O₄) and maghemite (γ-Fe₂O₃).

Protocol of animal experiments

Male BALB/c mice (5–6 weeks old) were purchased from the Animal Breeding Center of the National Taiwan University Hospital (Taipei, Taiwan). On arrival, the mice were randomized, transferred to plastic cages containing a sawdust bedding (five mice per cage), and quarantined for at least 1 week. The mice were given standard laboratory food and water ad libitum. The mice were randomly divided into the following groups (five mice per group; Figure 1): (1) nonsensitized (but ovalbumin-challenged) group; (2) untreated ovalbumin-sensitized and challenged group; (3) vehicle-treated plus ovalbumin-sensitized and challenged group; and (4) iron oxide nanoparticle-treated plus ovalbumin-sensitized and challenged group. A single dose of iron oxide nanoparticles (0.2–10 mg iron/kg; 0.2 mL/mouse) and/or vehicle (saline) were administered to mice via 

![Figure 1] Protocol of iron oxide nanoparticle administration and ovalbumin sensitization and challenge. BALB/c mice were randomly divided into the following groups (five mice per group): (1) nonsensitized (but ovalbumin-challenged) group; (2) untreated ovalbumin-sensitized and challenged group; (3) vehicle-treated (saline 0.2 mL/mouse) plus ovalbumin-sensitized and challenged group; and (4) iron oxide nanoparticle-treated (0.2–10 mg iron/kg, 0.2 mL/mouse) plus ovalbumin-sensitized and challenged group. The dosing regimen for iron oxide nanoparticle administration and antigen sensitization and challenge are described in the materials and methods.

Abbreviation: OVA, ovalbumin.
the tail vein 1 hour prior to ovalbumin sensitization on day zero. Except for the nonsensitized group, each mouse was sensitized with ovalbumin by a subcutaneous injection using 0.1 mL sensitization solution (100 µg ovalbumin and 1 mg alum in saline). The hind footpads of all mice were challenged subcutaneously with 20 µL of 10 µg ovalbumin in saline on day seven. DTH reactions represented by the degree of footpad swelling were measured using an electronic caliper, Model No. 4120 (King Life Technology Company Ltd, Taipei, Taiwan) before and 24 hours after the ovalbumin challenge. The paw swelling was determined as the following:

Footpad swelling (mm) = Footpad thickness after ovalbumin challenge − Footpad thickness before ovalbumin challenge.

The mice were then sacrificed, and their serum samples, spleens, and footpads were harvested for further measurements. All animal experiments were approved by the Institutional Animal Care and Use Committee of the National Taiwan University.

Histological analysis of footpads
The footpads of mice were fixed with 10% neutral buffered formalin for 1 day followed by decalcification for 2 days. The tissue specimens were embedded in paraffin, cut into 3–4 µm sections, and stained with hematoxylin and eosin for routine histopathology.

Immunohistochemical staining
The tissue sections were deparaffinized and then rehydrated following a standard procedure. The rehydrated slides were immersed in Trilogy™ (Cell Marque, Hot Springs, AR) at 121°C for 15 minutes for antigen retrieval. The endogenous peroxidase activity was then quenched with 3% hydrogen peroxide in methanol and blocked with normal horse serum. Antimouse CD3, F4/80, Foxp3, IFN-γ, IL-6, or TNF-α monoclonal antibodies were applied onto each section overnight. The slides were treated with super enhancer and then incubated with polyhorseradish peroxidase reagent. For visualization, the slides were treated with the peroxidase substrate 3-amino-9-ethylcarbazole followed by hematoxylin counter staining (blue color). The number of positive cells showing dark-red color was counted manually.

Splenocyte cultures and measurement of splenocyte viability
Spleens from the mice of the same group were aseptically isolated, pooled, and made into single cell suspensions as described previously. The viability of splenocytes was determined by the 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (methylthiazol tetrazolium) assay described previously. Splenocytes (5 × 10^6 cells/mL) were seeded into 96-well plates. The cells were either left unstimulated or stimulated with ovalbumin for 68 hours. A methylthiazol tetrazolium stock solution (5 mg/mL in phosphate buffered saline) was then added to each well (10 µL/well) and incubated for 4 hours. The formed formazan was dissolved with 0.1 N acid-isopropanol (100 µL/well); the optical density was measured at 570 nm (and at 630 nm as a background reference) using a microplate reader (Dynatech Laboratories Inc, Chantilly, VA).

Measurement of cytokines by enzyme-linked immunosorbent assay
Splenocytes (5 × 10^6 cells/mL) were cultured in 48-well plates (250 µL/well) followed by stimulation with ovalbumin (50 µg/mL) for 72 hours. The supernatants were harvested and quantified for IL-4 and IFN-γ by enzyme-linked immunosorbent assay.

Measurement of the phagocytic activity of splenic CD11b^+ cells
Splenic CD11b^+ cells were isolated using a commercial kit (BD IMag™ Cell Separation System; BD Biosciences) following the supplier’s protocol. The purity of isolated cells was confirmed to be ≥90% by flow cytometry (FACSCalibur™; BD Biosciences) using a fluorescein isothiocyanate-conjugated antimouse CD11b monoclonal antibody (clone M1/70; BD Biosciences). The phagocytic activity of the splenic CD11b^+ cells was measured using pH-sensitive pHrodo® *Escherichia coli* BioParticles™ conjugate (Invitrogen Life Technologies, Carlsbad, CA) following the manufacturer’s instructions. In brief, the CD11b^+ cells (5 × 10^6 cells/mL) were seeded into 96-well plates (0.1 mL/well) and cocultured with pHrodo *E. coli* BioParticles conjugate for 3 hours. After washing, cells were collected, and the single cell fluorescence of 5000 cells for each sample was measured at emission of 575 nm using a FACSCalibur flow cytometer.

Statistical analysis
The mean ± standard error was determined for each treatment group in the individual experiments. Homogeneous data were then evaluated by a parametric analysis of variance, and Dunnett’s two-tailed t-test was used to compare the results.
for the treatment groups with those of the control group. 
\( P < 0.05 \) was defined as statistical significance.

**Results**

**Administration of iron oxide nanoparticles suppressed DTH reactions**

The effect of iron oxide nanoparticles on DTH reactions was firstly investigated by measuring the swelling of footpads in mice sensitized and challenged with ovalbumin. Ovalbumin challenge markedly increased the thickness of footpads in ovalbumin-sensitized mice compared to the nonsensitized group (Figure 2A), signifying a successful induction of DTH. Iron oxide nanoparticles (0.6 and 10 mg iron/kg) showed a significant suppressive effect on footpad swelling, in which the inhibitory magnitude of the two doses was comparable, whereas the low dose (0.2 mg iron/kg) was ineffective (Figure 2A). Histological examination using hematoxylin and eosin staining showed a marked infiltration of mononuclear cells in subcutaneous tissues of the footpads in the untreated ovalbumin-sensitized and vehicle-treated groups, which appeared to be diminished by iron oxide nanoparticle administration (0.6 and 10 mg iron/kg; Figure 2B). To more specifically characterize the types of inflammatory cells influenced by iron oxide nanoparticles, the number of total T cells (CD3\(^+\)), regulatory T cells (Foxp3\(^+\)), and macrophages (F4/80\(^+\)) and the expression of IFN-\(\gamma\), IL-6, and TNF-\(\alpha\) in the footpads was measured by immunohistochemical staining. The signal of IFN-\(\gamma\), IL-6, and TNF-\(\alpha\) was primarily detected perivascularly in the dermis layer, which was markedly suppressed by iron oxide nanoparticle treatment (0.6 and 10 mg iron/kg; Figure 3A–C and Table 1). Furthermore, the number of CD3\(^+\) and F4/80\(^+\) cells was significantly suppressed in mice administered with iron oxide nanoparticles (0.6 and 10 mg iron/kg) compared to the vehicle-treated control (Table 1). In contrast, the infiltration of Foxp3\(^+\) cells was not altered by iron oxide nanoparticles (Table 1).

**Differential effects of iron oxide nanoparticles on T cell functionality**

Cytokines expressed by T cells play an essential role dictating antigen-specific immune reactions, including humoral and cell-mediated immunity. To investigate the influence of iron oxide nanoparticles on the functionality of T cells in DTH reactions, splenocytes harvested from nonsensitized and ovalbumin-sensitized mice were restimulated with ovalbumin (50 \(\mu\)g/mL) in culture for 72 hours to induce the production of antigen-specific cytokines. As shown in Figure 4, both IFN-\(\gamma\) and IL-4 were markedly induced by ovalbumin stimulation in the ovalbumin-sensitized groups compared to the nonsensitized group, demonstrating a successful induction of antigen-specific T cell reactivity. Consistent with the reduced footpad swelling, iron oxide nanoparticles (0.6 and 10 mg iron/kg)
demonstrated a suppressive effect on the production of IFN-γ (Figure 4A). By contrast, administration of iron oxide nanoparticles (0.6 and 10 mg iron/kg) enhanced the production of IL-4 (Figure 4B). As the expression of cytokines was influenced by iron oxide nanoparticle treatment, the viability of ovalbumin-stimulated splenocytes was further examined. The results from the methylthiazol tetrazolium assays showed that the viability of splenocytes was unaltered in mice administered with iron oxide nanoparticles (Figure 5).

Effects of iron oxide nanoparticles on phagocytic activity of CD11b⁺ splenocytes

To further examine the influence of iron oxide nanoparticles on the functionality of macrophages, the phagocytic activity of splenic CD11b⁺ cells was examined. The percentage of splenic CD11b⁺ cells engulfing the fluorescent probe pHrodo was significantly attenuated in mice administered with iron oxide nanoparticles (0.6 and 10 mg iron/kg; Figure 6A). Representative histograms of the pHrodo uptake by splenic CD11b⁺ cells in the vehicle-treated and iron oxide nanoparticle-treated (10 mg iron/kg) groups are illustrated in Figure 6B.

Discussion

Although iron oxide nanoparticles have been reported to affect the functionality of T cells and antigen-presenting cells, evidence pertaining to their effects on Th1 cell-mediated immunity in vivo remains mostly unknown. It was previously reported that systemic administration of ovalbumin-sensitized mice with iron oxide nanoparticles suppresses, the serum production of ovalbumin-specific immunoglobulin G1 and immunoglobulin G2a, and the expression of both IFN-γ and IL-4 by splenocytes. Moreover, a direct exposure of ovalbumin-primed splenocytes to iron oxide nanoparticles results in a reduced production of IFN-γ, but not IL-4. Because IFN-γ is a key cytokine expressed by Th1 cells, these results suggest that Th1 cells are potentially a more sensitive target to iron oxide nanoparticles compared to Th2 cells. It was therefore hypothesized that iron oxide nanoparticles may inhibit the DTH reactions in which Th1 cells play a central role in the elicitation of antigen-specific immune responses. This hypothesis was substantiated by the results in the present study, which show that the footpad swelling was suppressed by a single intravenous administration of iron oxide nanoparticles. Concordantly, the infiltration of T cells and the expression of IFN-γ in footpads were attenuated by iron oxide nanoparticle treatment.
Hence, the clinical dose of iron oxide nanoparticles plays a critical role dictating the effects of iron oxide nanoparticles on T cells, in which doses ≤10 mg iron/kg may shift the Th1/Th2 immunobalance toward the Th2-dominant direction in ovalbumin-sensitized mice. The potential impact of iron oxide nanoparticles on Th2 cell-mediated immunity, such as allergy, warrants further investigations using appropriate models.

The recommended doses of iron oxide nanoparticles as contrast agents to enhance the signal of magnetic resonance imaging are 25.2 mg iron (0.9 mL of Resovist) and 39.2 mg iron (1.4 mL) for adults weighing <60 kg and ≥60 kg, respectively.25,26 Hence, the clinical dose range of Resovist is greater than 0.42 mg iron/kg for adults weighing <60 kg and less than 0.65 mg iron/kg for adults weighing ≥60 kg. In the present study, the dose of 0.6 mg iron/kg was effective to curb DTH reactions, demonstrating the impact of iron oxide nanoparticles at a clinically relevant dose on Th1 cell-mediated immunity.

Previous studies reported that iron oxide nanoparticles activated macrophages and induced a proinflammatory effect when administered locally to the airways.15,27 In contrast, the present study showed a suppressive effect

Table 1 Immunohistochemical staining of CD3⁺, F4/80⁺, Foxp3, interferon-γ, interleukin-6, and tumor necrosis factor-α cells in the footpads of ovalbumin-sensitized and challenged mice

| Number of positive cells | Iron oxide nanoparticles (mg iron/kg) | NS | OVA | VH | 0.2 | 0.6 | 10 |
|--------------------------|--------------------------------------|----|-----|----|-----|-----|-----|
| CD3⁺                     |                                      | 16 ± 3 | 52 ± 9 | 67 ± 11 | 65 ± 4 | 25 ± 3* | 21 ± 4* |
| F4/80⁺                   |                                      | 3 ± 1 | 39 ± 4 | 33 ± 4 | 30 ± 5 | 10 ± 3* | 8 ± 2* |
| Foxp3⁺                   |                                      | 2 ± 1 | 5 ± 1 | 5 ± 1 | 5 ± 1 | 4 ± 1 | 4 ± 1 |
| IFN-α⁺                   |                                      | 4 ± 1 | 24 ± 5 | 24 ± 5 | 18 ± 3 | 6 ± 2* | 5 ± 1* |
| IL-6⁺                    |                                      | 5 ± 1 | 17 ± 3 | 18 ± 3 | 13 ± 2 | 6 ± 2* | 7 ± 1* |
| TNF-α⁺                   |                                      | 10 ± 2 | 56 ± 11 | 62 ± 16 | 50 ± 16 | 10 ± 2* | 7 ± 2* |

Notes: The footpad sections were stained with antibodies against CD3, F4/80, Foxp3, interferon-γ, interleukin-6, and tumor necrosis factor-α as described in the materials and methods. The number of positively stained cells was counted manually. Data are expressed as the mean ± standard error of six to eight footpads per group. Results are representative of three independent experiments. *P < 0.05 compared to the vehicle-treated group.

Abbreviations: IFN, interferon; IL, interleukin; NS, nonsensitized group; OVA, untreated ovalbumin-sensitized and challenged group; VH, vehicle-treated and ovalbumin-sensitized and challenged group.

It was previously reported that high doses (30 and 60 mg iron/kg) of iron oxide nanoparticles cause an overall suppressive effect on the expression of both Th1 and Th2 cytokines by splenocytes of ovalbumin-sensitized mice, whereas a low dose (10 mg iron/kg) affects the production of IFN-γ, but not IL-4.25 Hence, 10 mg of iron/kg was employed in the present study, and the results confirmed the sensitivity of IFN-γ to the dose of iron oxide nanoparticles. The study further extended to a lower dose (0.6 mg iron/kg) in mice with DTH, which enhanced the production of IL-4 (Figure 4). These results suggest that the dose of iron oxide nanoparticles plays a critical role dictating the effects of iron oxide nanoparticles on T cells, in which doses ≤10 mg iron/kg may shift the Th1/Th2 immunobalance toward the Th2-dominant direction in ovalbumin-sensitized mice.

Figure 4 Differential effects of iron oxide nanoparticles on the production of antigen-specific interferon-γ and interleukin-4 by splenocytes. Splenocytes isolated from each group of mice were cultured in the presence of ovalbumin (50 μg/mL) for 72 hours, and the supernatants were collected for measurement of (A) interferon-γ and (B) interleukin-4 by enzyme-linked immunosorbent assay. Note: Data are expressed as the mean ± standard error of six samples pooled from two experiments; *P < 0.05 compared to the vehicle-treated group.

Abbreviations: Fe, iron; NS, nonsensitized group; OVA, untreated ovalbumin-sensitized and challenged group; VH, vehicle-treated plus ovalbumin-sensitized and challenged group.
on the functionality of both macrophages and Th1 cells by systemically administered iron oxide nanoparticles. These results suggest that the way of administration may be a critical factor influencing the immunomodulatory effects of iron oxide nanoparticles. In addition, the nature of immune responses could be another key factor in that no antigen sensitization was applied in the airway studies, whereas the DTH reactions were antigen-specific. It is well established that both T cells and macrophages are involved in the pathophysiology of DTH, in which IFN-γ expressed by antigen-activated Th1 cells stimulates macrophages that subsequently trigger inflammatory responses. In light of this premise, it was speculated that the downregulated activities of macrophages in iron oxide nanoparticle-treated mice could be due to the suppressive effect of the nanoparticles on T cells. Obviously, the potential impact of iron oxide nanoparticles on the functionality of macrophages may be dictated by different routes of exposure. As demonstrated in the present study for the scenario of systemic exposure, iron oxide nanoparticles suppress the function of both macrophages and T cells in response to antigen stimulation. As Th cells play an essential role in the regulation of different arms of antigen-specific immunity, addressing the impact on the functionality of Th cells would be crucial for assessing the nanotoxicology of iron oxide nanoparticles when systemic exposure is concerned.

In addition to the route of exposure, antigen sensitization and challenge is another potential factor influencing the different effects induced by systemic and intratracheal administrations of iron oxide nanoparticles. The observed inhibition of DTH responses by iron oxide nanoparticles is in line with a recent report showing a similar suppressive effect by fullerene nanoparticles.29
is noticed that both studies employed intravenous injection for nanoparticle administration. However, the underlying mechanisms are quite different. The study of fullerene nanoparticles showed an enhanced number of regulatory T cells and an attenuated expression of the proinflammatory cytokines IL-6 and IL-17, whereas the expression of TNF-α was paradoxically enhanced. Hence, the mechanism of action for fullerene nanoparticles was attributed to an upregulation of the regulatory immunity. By contrast, the present data showed a concordant attenuation of the functionality of both Th1 cells and their downstream effector cells, namely macrophages, whereas the number of Foxp3+ cells in footpads was unaltered. The suppression of macrophage functions was further substantiated by the present data showing a significant attenuation of the expression of IL-6 and TNF-α in footpads and the phagocytic activity in splenic CD11b+ cells of iron oxide nanoparticle-treated mice. Collectively, despite different mechanisms of action, both fullerene and iron oxide nanoparticles elicit a similar suppressive effect on DTH, suggesting the potential health impact on Th1 immunity by systemic exposure of nanoparticles.

**Conclusion**

The present study demonstrated that a single administration of iron oxide nanoparticles at a clinically relevant dose attenuated DTH reactions. Iron oxide nanoparticles suppressed the systemic production of IFN-γ – a Th1 signature cytokine – by splenocytes, as well as locally in the inflamed footpads. In addition to T cells, the functionality of macrophages associated with DTH was attenuated, including the infiltration and expression of the proinflammatory cytokines IL-6 and TNF-α in the inflammatory site. These results provide critical insights into the health impact of iron oxide nanoparticles on cell-mediated immunity. The potential immunotoxicity of iron oxide nanoparticles warrants further investigation.

**Acknowledgments**

This work was supported by grants NSC98-2320-B-002-036-MY3 and NSC99-2313-B264-001-MY3 from the National Science Council, Executive Yuan (Taipei, Taiwan) and KMU-ER013 from Kaohsiung Medical University Research Foundation (Kaohsiung City, Taiwan).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Ito A, Shinkai M, Honda H, Kokayashi T. Medical application of functionalized magnetic nanoparticles. *J Biosci Bioeng*. 2005;100(1):1–11.
2. Huber DL. Synthesis, properties, and applications of iron nanoparticles. *Small*. 2005;1(5):482–501.
3. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. *Biomaterials*. 2005;26(18):3995–4021.
4. Hautot D, Pankhurst QA, Morris CM, Curtis A, Burn J, Dobson J. Preliminary observation of elevated levels of nanocrystalline iron oxide in the basal ganglia of neuroferritinopathy patients. *Biochim Biophys Acta*. 2007;1722(1):21–25.
5. Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with truce metal imbalance. *Neurosci Lett*. 2006;406(3):189–193.
6. Bulte JW, Douglas T, Witwer B, et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. *Nat Biotechnol*. 2001;19(12):1141–1147.
7. Hamm B, Staks T, Taupitz M, et al. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide. *J Magn Reson Imaging*. 1994;4(5):659–668.
8. Vogl TJ, Hammerstingl R, Pegios W, et al. The value of the liver-specific superparamagnetic contrast medium AMI-25 for the detection and differential diagnosis of primary liver tumors versus metastases. *Rofo*. 1994;160(4):319–328.
9. Josephson L, Lewis J, Jacobs P, Hahn PF, Stark DD. The effects of iron oxides on proton relaxivity. *Magn Reson Imaging*. 1988;6(6):647–653.
10. McLachlan SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. *J Magn Reson Imaging*. 1994;3(3):301–307.
11. Reimer P, Muller M, Marx C, et al. T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration – preliminary clinical experience with dynamic T1-weighted MR imaging. *Radiology*. 1998;209(3):831–836.
12. Wang J, Chen Y, Chen B, et al. Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticles in mice. *Int J Nanomedicine*. 2010;5:861–866.
13. Lunov O, Syroverts T, Bucele B, et al. The effect of carboxydextran-coated superparamagnetic iron oxide nanoparticles on c-Jun N-terminal kinase-mediated apoptosis in human macrophages. *Biomaterials*. 2010;31(19):5063–5071.
14. Hsiao JK, Chu HH, Wang YH, et al. Macrophage physiological function after superparamagnetic iron oxide labeling. *NMR Biomed*. 2008;21(8):820–829.
15. Park EI, Kim H, Kim Y, Yi J, Choi K, Park K. Inflammatory responses may be induced by a single intratracheal instillation of iron nanoparticles in mice. *Toxicology*. 2010;275(1–3):65–71.
16. Chen BA, Jin N, Wang J, et al. The effect of magnetic nanoparticles of Fe(3)O(4) on immune function in normal ICR mice. *Int J Nanomedicine*. 2010;5:593–599.
17. Wang J, Chen B, Jin N, et al. The changes of T lymphocytes and cytokines in ICR mice fed with Fe3O4 magnetic nanoparticles. *Int J Nanomedicine*. 2011;6:605–610.
18. Shen CC, Liang HJ, Wang CC, Liao MH, Jan TR. A role of cellular glutathione in the differential effects of iron oxide nanoparticles on antigen-specific T cell cytokine expression. *Int J Nanomedicine*. 2011;6:2791–2798.
19. Shen CC, Wang CC, Liao MH, Jan TR. A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice. *Int J Nanomedicine*. 2011;6:1229–1235.
20. Cher DJ, Mosmann TR. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. *J Immunol*. 1987;138(11):3688–3694.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods*. 1983;65(1–2):55–63.

22. Jan TR, Su ST, Wu HY, Liao MH. Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of spleenocytes in ovalbumin-sensitized BALB/c mice. *Int Immunopharmacol*. 2007;7(6):773–780.

23. Blank F, Gerber P, Rothen-Rutishauser B, et al. Biomedical nanoparticles modulate specific CD4+ T cell stimulation by inhibition of antigen processing in dendritic cells. *Nanotoxicology*. 2011;5(4):606–621.

24. Naqvi S, Samim M, Abdin M, et al. Concentration-dependent toxicity of iron oxide nanoparticles mediated by increased oxidative stress. *Int J Nanomedicine*. 2010;5:983–989.

25. Reimer P, Balzer T. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. *Eur Radiol*. 2003;13(6):1266–1276.

26. Resovist® [package insert]. Berlin: Bayer Schering Pharma AG; 2002.

27. Zhu MT, Feng WY, Wang B, et al. Comparative study of pulmonary responses to nano- and submicron-sized ferric oxide in rats. *Toxicology*. 2008;247(2–3):102–111.

28. Kobayashi K, Kaneda K, Kasama T. Immunopathogenesis of delayed-type hypersensitivity. *Microsc Res Tech*. 2001;53(4):241–245.

29. Yamashita K, Sakai M, Takemoto N, et al. Attenuation of delayed-type hypersensitivity by fullerene treatment. *Toxicology*. 2009;261(1–2):19–24.